Olema Pharmaceuticals (OLMA) Free Cash Flow (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of Free Cash Flow data on record, last reported at -$46.0 million in Q1 2026.

  • On a quarterly basis, Free Cash Flow fell 4.57% to -$46.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$148.7 million, a 19.13% decrease, with the full-year FY2025 number at -$146.7 million, down 40.38% from a year prior.
  • Free Cash Flow reached -$46.0 million in Q1 2026 per OLMA's latest filing, down from -$38.3 million in the prior quarter.
  • Over the last five years, Free Cash Flow for OLMA hit a ceiling of -$17.9 million in Q1 2022 and a floor of -$46.0 million in Q1 2026.
  • A 5-year average of -$27.3 million and a median of -$26.3 million in 2024 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: crashed 174.52% in 2022, then grew 16.48% in 2023.
  • Tracing OLMA's Free Cash Flow over 5 years: stood at -$19.9 million in 2022, then increased by 7.08% to -$18.5 million in 2023, then plummeted by 42.26% to -$26.3 million in 2024, then crashed by 45.82% to -$38.3 million in 2025, then dropped by 19.99% to -$46.0 million in 2026.
  • Business Quant data shows Free Cash Flow for OLMA at -$46.0 million in Q1 2026, -$38.3 million in Q4 2025, and -$34.5 million in Q3 2025.